Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- AstraZeneca's Diprivan Inj-Kit to Contribute to Preventing Accidents
May 7, 2001
- REGULATORY NEWS IN BRIEF
May 7, 2001
- Atorvastatin Raises Treatment Target Achievement Rates: Yamanouchi/Pfizer Seminar
May 7, 2001
- Japanese Global Strategy Update (1)
May 7, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -1-
May 7, 2001
- Pricing Rule for Innovative Medical Devices to Be Studied
May 7, 2001
- DIAGNOSTIC NEWS IN BRIEF
May 7, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -3-
May 7, 2001
- GPMSP Guidelines for Medical Devices to Go into Effect in October
May 7, 2001
- Takara Shuzo's Dragon Genomics Starts Full Operation
May 7, 2001
- WORLD NEWS IN BRIEF
May 7, 2001
- MEDICAL DEVICE NEWS IN BRIEF
May 7, 2001
- Chugai Establishes Chugai Pharma France in Paris
May 7, 2001
- Identification of Genes Related to Medical Diseases Expected within 10 Years
May 7, 2001
- BULLETIN
May 7, 2001
- MTP to Independently Market Grtpa
May 7, 2001
- Multidrug Resistance Seen in 6.2% of Tuberculosis Patients
May 7, 2001
- Nikken Chemical to Codevelop Sustained-release hGH with InfiMed of the US
May 7, 2001
- Fujisawa, ORIX Capital Establishes New Investment Fund
April 23, 2001
- OBITUARY
April 23, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…